MedWatch

Biogen's Aduhelm rejected by EMA committee

As expected, the European Medicines Agency's (EMA) special committee, the CHMP, has given a negative opinion on Alzheimer's treatment, Aduhelm, as Biogen proved unable to convince the authority to approve the drug as managed to do in the US.

Photo: POOL New/VIA REUTERS / X80003

On Friday, Alzheimer's drug Aduhelm, which pharmaceutical firm Biogen is behind, has been rejected by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

The negative opinion is tantamount to a refusal to grant marketing authorization in Europe. Should Biogen choose to do so, it now has 15 days to ask for re-examination, reports Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs